CN103525639A - Pyrroloquinoline quinone-containing wine - Google Patents
Pyrroloquinoline quinone-containing wine Download PDFInfo
- Publication number
- CN103525639A CN103525639A CN201310499832.8A CN201310499832A CN103525639A CN 103525639 A CN103525639 A CN 103525639A CN 201310499832 A CN201310499832 A CN 201310499832A CN 103525639 A CN103525639 A CN 103525639A
- Authority
- CN
- China
- Prior art keywords
- wine
- pyrroloquinoline quinone
- mouse
- liver
- gavage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention provides a pyrroloquinoline quinone-containing wine. The wine comprises the following components in percentage: 0.01-10 percent of pyrroloquinoline quinone, 0.01-1 percent of stabilizer, 0.01-1 percent of cosolvent and 88-99.9 percent of wine. The pyrroloquinoline quinone-containing wine can specifically prevent alcoholic fatty liver and inhibit the process of diseases and has a good market prospect.
Description
Technical field
The present invention relates to a kind of health promoting beverage, be specifically related to a kind of Pyrroloquinoline quinone that contains and can prevent the wine of fatty liver.
Background technology
Chinese drink above history in 5000.Present stage, the rate of drinking of China's population is 59.5%, and wherein the male sex is 84.6%, and women is 29.4%, and a year drinking amount is 3.6L straight alcohol per capita.By epidemiology survey, the rates of drinking such as the good government functionary of economic situation, businessman, soldier are the highest, and the male sex is all higher than women.
Alcohol has obvious toxic action to liver: ethanol enters after liver cell, and the effect of a series of enzymes of process is oxidized to acetaldehyde.Excessive consumption of alcohol, a large amount of acetaldehyde has obvious toxic action to liver cell, directly or indirectly causes hepatocellular degeneration, necrosis and fibrosis, when serious, can develop into liver cirrhosis.The a series of pathologies such as liver damage that cause due to excessive absorption alcohol are called as alcoholic liver disease (alcoholicliverdisease, ALD).Hepatology branch of Chinese Medical Association is divided into 5 types of light-duty ALD, alcoholic fatty liver, alcoholic hepatitis, alcoholic fibrosis and alcoholic cirrhosises according to the pathological change of alcoholic liver disease by ALD.
In the U.S., ALD occupies the 10th in the cause of the death, has every year 1.5～20,000 people to die from ALD.The medical expense that only the 1994 Nian， U.S. pay because of ALD has just surpassed 2,500,000,000 dollars.Britain is every year because of liver cirrhosis and chronic hepatopathy died approximately 3000 examples, and wherein approximately 1200 examples are ALD.In recent years, also there is the trend increasing in the ，ALD China that improves along with living condition.According to domestic clinical criteria, the essence of drinking day amount surpasses 40 grams (closing 100 milliliters of 50 degree white wine, approximately 2 liang), and within continuous 5 years, above patient is alcoholist, more than 48% suffers from alcoholic liver disease in various degree in these crowds.Drinking-associated has become large medical science and the social concern that China faces, and alcoholic liver disease also more and more causes people's concern.
Summary of the invention
For the problems referred to above, the invention provides a kind of wine that can prevent alcoholic fatty liver.
For achieving the above object, the present invention adopts following technical scheme:
The invention provides a kind of wine containing Pyrroloquinoline quinone.
Above-mentioned wine comprises following component and content: Pyrroloquinoline quinone 0.01%～10%, and stablizer: 0.01%～1%, solubility promoter 0.01%～1%, wine 88%～99.9%.
Be preferably, this wine comprises following component and content: Pyrroloquinoline quinone 0.1%～1%, and stablizer: 0.1～0.5%, solubility promoter 0.1%～0.5%, wine 98%～99.7%.
More preferably, this wine comprises following component and content: Pyrroloquinoline quinone 0.5%, and stablizer: 0.2%, solubility promoter 0.2%, wine 99.1%.
Aforementioned stable agent includes but not limited to lactose, sucrose, mannitol, glucose, mannitol, Microcrystalline Cellulose etc.
Above-mentioned solubility promoter includes but not limited to L-glutamic acid, glycine, glutamine, arginine etc.
Above-mentioned wine includes but not limited to white wine, beer, fruit wine, yellow rice wine etc.
In wine provided by the invention, contain Pyrroloquinoline quinone, Pyrroloquinoline quinone is the prothetic group of multiple enzyme in bacterium, and can affect the level of respiratory chain function and interior free yl.Pyrroloquinoline quinone in the present invention has following physiological function: (1) is anti-oxidant; (2) liver injury that contratoxin causes plays protective effect; (3) accelerate the degraded to ethanol; (4) promote nerve growth effect.Visible, Pyrroloquinoline quinone can be blocked several approach that fatty liver forms.
Pyrroloquinoline quinone in the present invention can, in the situation that continuing to drink, can suppress the change AST of multiple enzyme in course of liver damage, ALT ..., then reverse the morphological change of fatty liver.Visible, it can specificity prevent alcoholic fatty liver the wine containing Pyrroloquinoline quinone of the present invention, suppresses the process of disease, has good market outlook.
Embodiment
Following examples are used for further illustrating content of the present invention, but should not be construed as limitation of the present invention.Without departing from the spirit and substance of the case in the present invention, the modification that the inventive method, step or condition are done or replacement, all belong to scope of the present invention.
The percentage sign relating in the present invention " % ", if not specified, refers to mass percent.
Embodiment 1 is containing the preparation of Pyrroloquinoline quinone wine
The preparation of Pyrroloquinoline quinone is specifically referring to Chinese patent 02111549.4.By GCpqq303 bacterial strain at substratum (0.3% (NH
4)
2sO
4, 0.14%KH
2pO
4, 0.01%MgSO
4, 0.05%FeCl
3, 0.8% methyl alcohol), cultivate 14 days for 30 degrees Celsius.Carry out above expression three times, obtainable expression amount is 3～4mg/l approximately.
Fermented liquid supernatant, through boiling, is adsorbed in after centrifuging on FPLC-Q post, and through salt gradient wash-out, collects Peak Activity.The Pyrroloquinoline quinone obtaining detects through FPLC method, and purity is more than 90%, and yield is 56%.
Embodiment 2 is the prophylactic effect to fatty liver containing the wine of Pyrroloquinoline quinone
Kunming mice is divided into 6 groups, 12 every group, male and female half and half, mean body weight is 25g, the wine to each group gavage containing the Pyrroloquinoline quinone of different amounts.Concrete gavage grouping is in Table 1:
Table 1: the concrete composition of each test group gavage
| Group | Pyrroloquinoline quinone | Sucrose | L-glutamic acid |
| Test group 1 | 0.1g | 0.1g | 0.1g |
| Test group 2 | 1g | 1g | 1g |
| Test group 3 | 5g | 2g | 2g |
| Test group 4 | 10g | 5g | 5g |
| Test group 5 | 20g | 5g | 5g |
Pyrroloquinoline quinone in each test group in upper table, sucrose, L-glutamic acid are dissolved in respectively in 1L white wine (40 degree) and make 5 groups containing the wine of the Pyrroloquinoline quinone of different amounts, and the test group that is common white spirit by gavage is made as control group.
12 mouse stomaches in giving every group respectively by the wine of above-mentioned 6 test group, the amount of gavage is every 0.25ml/ days, carries out continuously 15 days.After experimentation on animals finishes, get mouse liver, liver, through paraffin section, after dyeing, is observed the physiological change of liver organization.
Each is found after organizing mouse liver section statining, there are a large amount of cavitys around in the nucleus of the mouse liver of control group, and mouse in test group 1 only has 3 to occur a small amount of cavity, testing in 2 groups has a mouse to observe several cavitys, mouse in other groups does not all observe cavity, the visible amount that reaches the Pyrroloquinoline quinone in test group 3 just can effectively be prevented fatty liver, test group 4 and 5 is to strengthen the test group of the amount of Pyrroloquinoline quinone again, result, the effect of its prevention fatty liver is compared with test group 3 significant lifting is not occurred yet, but it is many that the production cost of two groups rises.Therefore,, after considering production cost, visible test group 3 is best selection schemes.The above results can show, the wine that contains Pyrroloquinoline quinone has certain prophylactic effect to fatty liver.
The prophylactic effect of the wine that contains Pyrroloquinoline quinone that embodiment 3 is dissimilar to fatty liver
Choose six kinds of wine of Kaoliang spirit, corn wine, white wine, red wine, yellow rice wine, beer of the identical number of degrees (40 degree), get above-mentioned 6 kinds of each 1L of wine kind, add respectively Pyrroloquinoline quinone 0.1g, sucrose 0.1g, L-glutamic acid 0.1g as test group 1; In above-mentioned 6 kinds of wine, add respectively Pyrroloquinoline quinone 1g, sucrose 1g, L-glutamic acid 1g as test group 2.
72 mouse stomaches (every kind of wine gavage mouse is 12) in giving every group respectively by the wine of above-mentioned 2 test group, the amount of gavage is every 0.25ml/ days, carries out continuously 15 days.After experimentation on animals finishes, get mouse liver, liver, through paraffin section, after dyeing, is observed the physiological change of liver organization.
After test group 1 mouse liver section statining, find, 12 mouse of Kaoliang spirit gavage have 4 to occur a small amount of cavity, the mouse of corn wine gavage also has 4 to occur a small amount of cavity, in 12 mouse of white wine gavage, there are 3 to occur cavity, and the mouse of red wine gavage only has 2 to occur cavity, there is cavity in 3 of the mouse of yellow rice wine gavage, the mouse of beer gavage is also 4 and has occurred cavity.
After testing 2 groups of mouse liver section statinings, find, 12 mouse of Kaoliang spirit gavage have 1 to occur a small amount of cavity, the mouse of corn wine gavage also has 1 to occur a small amount of cavity, in 12 mouse of white wine gavage, there is 1 to occur cavity, and all there is not cavity in all mouse of red wine gavage, there is not the mouse of cavity in the mouse of yellow rice wine gavage, the mouse of beer gavage is also 1 and has occurred cavity yet.
The above results shows, adds the Pyrroloquinoline quinone of same amount in different types of wine, and institute plays and prevents the effect of fatty liver and be not quite similar, and the effect of some wine will obviously be better than other wine.Visible, the Pyrroloquinoline quinone of interpolation and some beneficiating ingredient in wine play complementary effect.
The stability of embodiment 3 Pyrroloquinoline quinones in wine
After completing, continues embodiment 2 to deposit the above-mentioned wine that adds Pyrroloquinoline quinone, just finish test in embodiment 2 and used afterwards in active electrophoresis method experiment with measuring group 2 content of Pyrroloquinoline quinone in various wine, experimental result shows, the Pyrroloquinoline quinone in wine is not degraded.Place after 1,3,6,12,24 month and to continue to measure above-mentioned various wine, the pyrroloquinoline quinone content in the various wine of test group 2 does not all change, and result shows, Pyrroloquinoline quinone is highly stable in wine.
Claims (6)
1. containing a wine for Pyrroloquinoline quinone, it is characterized in that, this wine comprises following component and content: Pyrroloquinoline quinone 0.01%～10%, stablizer 0.01%～1%, solubility promoter 0.01%～1%, wine 88%～99.9%.
2. according to the wine shown in claim 1, it is characterized in that, this wine comprises following component and content: Pyrroloquinoline quinone 0.1%～1%, stablizer 0.1～0.5%, solubility promoter 0.1%～0.5%, wine 98%～99.7%.
3. wine according to claim 1 and 2, is characterized in that, this wine comprises following component and content: Pyrroloquinoline quinone 0.5%, stablizer 0.2%, solubility promoter 0.2%, wine 99.1%.
4. according to the wine described in claim 1～3 any one, it is characterized in that, aforementioned stable agent is selected from lactose, sucrose, mannitol, glucose, mannitol or Microcrystalline Cellulose.
5. wine according to claim 4, is characterized in that, above-mentioned solubility promoter is selected from L-glutamic acid, glycine, glutamine or arginine.
6. wine according to claim 5, is characterized in that, above-mentioned wine is selected from white wine, beer, fruit wine or yellow rice wine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310499832.8A CN103525639B (en) | 2013-10-22 | 2013-10-22 | A kind of wine containing Pyrroloquinoline quinone |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310499832.8A CN103525639B (en) | 2013-10-22 | 2013-10-22 | A kind of wine containing Pyrroloquinoline quinone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103525639A true CN103525639A (en) | 2014-01-22 |
| CN103525639B CN103525639B (en) | 2015-09-16 |
Family
ID=49927994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310499832.8A Expired - Fee Related CN103525639B (en) | 2013-10-22 | 2013-10-22 | A kind of wine containing Pyrroloquinoline quinone |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103525639B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018180885A1 (en) * | 2017-03-28 | 2018-10-04 | 三菱瓦斯化学株式会社 | Jelly containing pyrroloquinoline quinone |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1454595A (en) * | 2002-04-29 | 2003-11-12 | 上海医学生命科学研究中心有限公司 | Pharmaceutical composition comprising pyrroloquinoline quinone for curing and preventing fatty liver |
| CN1939403A (en) * | 2005-09-26 | 2007-04-04 | 孙毅 | Production of compound Danshen root injection |
| CN101278907A (en) * | 2008-05-28 | 2008-10-08 | 喻文涛 | Coenzyme Q10 injection |
| CN101889978A (en) * | 2010-04-29 | 2010-11-24 | 袁璐 | Pharmaceutical composition containing vinpocetine, preparation method and application thereof |
| JP2011024476A (en) * | 2009-07-24 | 2011-02-10 | Mitsubishi Gas Chemical Co Inc | Pyrroloquinolinequinone-containing alcohol |
-
2013
- 2013-10-22 CN CN201310499832.8A patent/CN103525639B/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1454595A (en) * | 2002-04-29 | 2003-11-12 | 上海医学生命科学研究中心有限公司 | Pharmaceutical composition comprising pyrroloquinoline quinone for curing and preventing fatty liver |
| CN1939403A (en) * | 2005-09-26 | 2007-04-04 | 孙毅 | Production of compound Danshen root injection |
| CN101278907A (en) * | 2008-05-28 | 2008-10-08 | 喻文涛 | Coenzyme Q10 injection |
| JP2011024476A (en) * | 2009-07-24 | 2011-02-10 | Mitsubishi Gas Chemical Co Inc | Pyrroloquinolinequinone-containing alcohol |
| CN101889978A (en) * | 2010-04-29 | 2010-11-24 | 袁璐 | Pharmaceutical composition containing vinpocetine, preparation method and application thereof |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018180885A1 (en) * | 2017-03-28 | 2018-10-04 | 三菱瓦斯化学株式会社 | Jelly containing pyrroloquinoline quinone |
| CN110461168A (en) * | 2017-03-28 | 2019-11-15 | 三菱瓦斯化学株式会社 | Jelly containing pyrroloquinoline quinone |
| JPWO2018180885A1 (en) * | 2017-03-28 | 2020-02-06 | 三菱瓦斯化学株式会社 | Jelly containing pyrroloquinoline quinone |
| JP7167911B2 (en) | 2017-03-28 | 2022-11-09 | 三菱瓦斯化学株式会社 | Pyrroloquinoline quinone-containing jelly |
| CN110461168B (en) * | 2017-03-28 | 2023-02-17 | 三菱瓦斯化学株式会社 | Jelly containing pyrroloquinoline quinone |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103525639B (en) | 2015-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102994305B (en) | Method for preparing health-care food (therapy) product (nutrient juice wine) by use of extracts from cordyceps militaris and cocoon | |
| CN101850010B (en) | Active extract of citrus peels as well as extraction process and application thereof | |
| CN103859082B (en) | Gold flower big red robe tea and processing technology thereof | |
| CN102391917A (en) | Microbial cleaning agent for pesticides on fruits and vegetables and preparation method for microbial cleaning agent | |
| CN104522812B (en) | A kind of Cordyceps sinensis viable bacteria beverage and production method thereof | |
| CN102965267A (en) | Health care vinegar beverage | |
| CN103911259B (en) | A kind of raspberry Liquor and brewing method thereof | |
| CN104987316A (en) | Marine fungus-derived polyketone compound and application thereof in treatment of type 2 diabetes | |
| CN103976351A (en) | Health food capable of enhancing immunity and improving sleep and two-step fermentation preparation method thereof | |
| CN104212726A (en) | Liquid fermentation culture medium for antrodia camphorata | |
| CN103525639B (en) | A kind of wine containing Pyrroloquinoline quinone | |
| CN103351281B (en) | Marine-derived sesterterpene compounds, preparation method and application thereof | |
| KR101799400B1 (en) | Medium composition comprising amino acids for sparassis latifolia mycelium and the production method of the sparassis latifolia mycelium with improved gamma-amino butyrate using the same | |
| CN103948023A (en) | Health foods for enhancing immunity and improving sleep and two-step fermentation preparation method thereof | |
| CN109825533A (en) | A kind of fermentation medium and its fermentation culture method being used to prepare high activity Phellinus tunning | |
| CN104876684A (en) | Mother culture medium for artificial cultivation of oudemansiella radicata and preparation method of mother culture medium | |
| CN102987501B (en) | Method for preparing nutrient (liquid) beverages and granules of healthcare food (therapy) products by using extractives of cordyceps militaris and cocoons | |
| CN106261415A (en) | A kind of trifoliate orange Radix Ginseng compound hangover-alleviatingsoybean beverage and preparation method thereof | |
| CN102987405B (en) | Method for preparing health food capsules by using cordyceps militaris and cocoon extracts | |
| CN102125132A (en) | Complex enzyme for extracting green tea and solution thereof | |
| CN102987408A (en) | Method for extracting nutritional ingredients such as free amino acids from waste cordyceps militaris cocoons | |
| CN105167061A (en) | Potato health care product and preparation method and application thereof | |
| CN101407767A (en) | Method for producing Chinese caterpillar fungus by fermentation | |
| CN108112841A (en) | A kind of cordyceps drink and preparation method thereof | |
| CN106497795A (en) | A kind of Cordyceps funguss seed culture medium containing Fructus Lycii and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150916 Termination date: 20161022 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |